Antibody-based therapeutics represent one of the largest and fastest growing drug modalities in the world. In 2019, antibody-based therapeutics accounted for over 140 billion dollars annual sales worldwide and represented five of the top 10 selling therapeutics. Today, hundreds of companies worldwide are developing antibody-based therapies with the goal of improving outcomes for patients in need.
In this webinar, Alloy Therapeutics, a leader in human antibody-based drug discovery platform technologies and discovery services, will share its perspectives on best practices for preclinical antibody drug discovery, review Alloy’s current offerings, and provide an open Q&A for all participants.
Participation is free, however registration is required before February 17, 2021.
